Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency forCD20on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding toCD20on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma^[1][2].

Liquid

2229047-91-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.